Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jacob J. Chabon, Andrew Simmons, Aaron M. Newman, Alexander F. Lovejoy, Mohammad S Esfahani, Henry Haringsma, David Matthew Kurtz, Henning Stehr, Florian Scherer, Kathleen A. Durkin, Gregory Alan Otterson, William T. Purcell, D. Ross Camidge, Jonathan Wade Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn
Institutions: Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford Medicine, Stanford Cancer Institute, Clovis Oncology (United States), University of California, Berkeley, The Ohio State University, University of Colorado Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2892004169